Table_1_Is sCD163 a Clinical Significant Prognostic Value in Cancers? A Systematic Review and Meta-Analysis.docx

BackgroundTumor associated macrophages (TAMs), a kind of inflammatory cells in the tumor microenvironment, are crucial for the occurrence and development of various tumors which increased the expression of CD163. Nevertheless, not much has been established regarding soluble CD163 and its connection to tumor diagnosis. In this case, a meta-analysis was conducted to determine the tumor diagnostic importance of serum sCD163.MethodsIn order to assess the correlation between sCD163 and the overall survival (OS) or progression-free survival (PFS) among tumor patients, a systematic perusal of literature published until June 2020 was conducted. Relevant data were primarily obtained from papers that have the following qualifications: 1) a confidence interval (CI) of 95%; 2) a report of the hazard ratios; and, 3) pooled by means of the Mantel–Haenszel random-effect representation.ResultsFor the final meta-analysis, eight papers comprised of 1,236 cases were involved. Through pooled investigation, it was determined that a correlation exists between elevated serum sCD163 and worse OS (HR = 2.24, 95% CI: 1.50–3.35, P

背景：肿瘤相关巨噬细胞（TAMs），肿瘤微环境中的炎症细胞，对于多种肿瘤的发生与发展至关重要，这些肿瘤增加了CD163的表达。然而，关于可溶性CD163及其与肿瘤诊断的联系，尚未有充分的建立。在此情况下，进行了一项荟萃分析，以确定血清sCD163在肿瘤诊断中的重要性。方法：为了评估sCD163与肿瘤患者总生存期（OS）或无进展生存期（PFS）之间的相关性，对截至2020年6月发表的文献进行了系统检索。相关数据主要来源于符合以下条件的论文：1）置信区间（CI）为95%；2）报告了风险比；以及，3）通过Mantel-Haenszel随机效应模型进行荟萃分析。结果：在最终的荟萃分析中，包括8篇论文，共涉及1,236个病例。通过荟萃研究，确定了高血清sCD163与较差的OS之间存在相关性（HR = 2.24，95% CI：1.50–3.35，P